Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $135

Benzinga Newsdesk www.benzinga.com Positive 81.0%

Neg 0% Neu 0% Pos 81%

Canaccord Genuity analyst Edward Nash maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $110 to $135.